PDF(Pubmed)
Abstract：
BACKGROUND: We aimed to compare 7 newer immunotherapies and targeted therapies for platinum-resistant relapsed ovarian cancer.
METHODS: We conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library electronic databases for phase III trials involving platinum-resistant recurrent ovarian cancer (PRrOC) patients treated with immunotherapy or targeted therapy in combination with chemotherapy. The quality of the included trials was assessed using the GRADE method. The primary outcome of comparison was progression-free survival, and secondary outcomes included overall survival and safety.
RESULTS: This analysis included 7 randomized phase III controlled trials, encompassing 2485 PRrOC patients. Combining bevacizumab plus chemotherapy and lurbinectedin demonstrated statistically significant differences in progression-free survival compared to all other regimens of interest. However, no statistically significant differences were observed in the overall survival. Nivolumab and mirvetuximab exhibited fewer serious adverse events than the other regimens of interest.
CONCLUSIONS: Our findings indicate that bevacizumab combined with chemotherapy and lurbinectedin monotherapy has significant efficacy in patients with PRrOC. For patients with PRrOC who have exhausted treatment options, nivolumab and mirvetuximab may be considered as alternatives because of their better safety profiles.
METHODS: We conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library electronic databases for phase III trials involving platinum-resistant recurrent ovarian cancer (PRrOC) patients treated with immunotherapy or targeted therapy in combination with chemotherapy. The quality of the included trials was assessed using the GRADE method. The primary outcome of comparison was progression-free survival, and secondary outcomes included overall survival and safety.
RESULTS: This analysis included 7 randomized phase III controlled trials, encompassing 2485 PRrOC patients. Combining bevacizumab plus chemotherapy and lurbinectedin demonstrated statistically significant differences in progression-free survival compared to all other regimens of interest. However, no statistically significant differences were observed in the overall survival. Nivolumab and mirvetuximab exhibited fewer serious adverse events than the other regimens of interest.
CONCLUSIONS: Our findings indicate that bevacizumab combined with chemotherapy and lurbinectedin monotherapy has significant efficacy in patients with PRrOC. For patients with PRrOC who have exhausted treatment options, nivolumab and mirvetuximab may be considered as alternatives because of their better safety profiles.
摘要：
背景：我们的目的是比较7种新的免疫疗法和靶向疗法治疗铂耐药的复发性卵巢癌。
方法：我们对PubMed进行了全面搜索，EMBASE,和CochraneLibrary电子数据库，用于涉及接受免疫治疗或靶向治疗联合化疗治疗的铂耐药复发性卵巢癌（PRrOC）患者的III期试验。使用GRADE方法评估纳入试验的质量。比较的主要结果是无进展生存期，次要结局包括总生存率和安全性.
结果：本分析包括7项III期随机对照试验，包括2485名PRrOC患者。与所有其他感兴趣的方案相比，贝伐单抗联合化疗和lurbinectedin在无进展生存期方面表现出统计学上的显着差异。然而,总生存期无统计学差异.Nivolumab和mirvetuximab表现出比其他感兴趣的方案更少的严重不良事件。
结论：我们的研究结果表明，贝伐单抗联合化疗和lurbinectedin单药治疗PRrOC患者具有显著疗效。对于已经用尽治疗方案的PRrOC患者，由于nivolumab和mirvetuximab具有更好的安全性,因此可以考虑作为替代方案.
方法：我们对PubMed进行了全面搜索，EMBASE,和CochraneLibrary电子数据库，用于涉及接受免疫治疗或靶向治疗联合化疗治疗的铂耐药复发性卵巢癌（PRrOC）患者的III期试验。使用GRADE方法评估纳入试验的质量。比较的主要结果是无进展生存期，次要结局包括总生存率和安全性.
结果：本分析包括7项III期随机对照试验，包括2485名PRrOC患者。与所有其他感兴趣的方案相比，贝伐单抗联合化疗和lurbinectedin在无进展生存期方面表现出统计学上的显着差异。然而,总生存期无统计学差异.Nivolumab和mirvetuximab表现出比其他感兴趣的方案更少的严重不良事件。
结论：我们的研究结果表明，贝伐单抗联合化疗和lurbinectedin单药治疗PRrOC患者具有显著疗效。对于已经用尽治疗方案的PRrOC患者，由于nivolumab和mirvetuximab具有更好的安全性,因此可以考虑作为替代方案.
